search
Back to results

PK of Serelaxin in Severe Renal Impairment and ESRD (CRLX030A2102)

Primary Purpose

Renal Failure, Chronic, End-Stage Renal Disease

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Serelaxin
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Renal Failure, Chronic focused on measuring Renal disease, renal impairment, End stage renal disease, Healthy volunteer, Pharmacokinetics

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

All subjects

- at least 50 years; body mass index (BMI) within the range of 18 - 35 kg/m2.

Patients with severe renal impairment / ESRD

  • Severe renal impairment (clinically significantly abnormal creatinine and creatinine clearance (15mL/min/1.73m2≤eGFR<30mL/min/1.73m2) or ESRD on hemodialysis.
  • Sitting vital signs should be within the following ranges:
  • oral body temperature between 35.0-37.5 °C
  • systolic blood pressure, 110 to 170 mm Hg
  • diastolic blood pressure, 60 to 105 mm Hg
  • pulse rate, 45 - 100 bpm

Healthy subjects

  • eGFR > 90mL/min/1.73m2;
  • matching in race, age (±10 years), gender, BMI (±15%) to a subject with renal impairment
  • Subject must be in good health.
  • Sitting vital signs should be within the following ranges:
  • oral body temperature between 35.0-37.5 °C
  • systolic blood pressure, 100 to 150 mm Hg
  • diastolic blood pressure, 60 to 95 mm Hg
  • pulse rate, 50 to 100 bpm

Exclusion Criteria:

All subjects

  • History of clinically significant ECG abnormalities at Screening or Baseline.
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential unless they are using highly effective methods of contraception during dosing of study treatment.
  • Sexually active males (incl. vasectomized men) must use a condom during intercourse while taking drug and for 2 weeks after stopping study medication.
  • Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).

Patients with severe renal impairment / ESRD:

  • Presence of any non-controlled and clinically significant disease, surgical or medical condition that could affect the study outcome or that would place the patient at undue risk as judged by the investigator.
  • Hemoglobin levels below 9.0 g/dL at screening and baseline, other laboratory parameters at screening and baseline outside acceptable limits .
  • Treatment with any cytostatic drug or autonomic alpha blocker.

Healthy subjects:

  • Use of any prescription drugs (other than hormonal contraception, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.
  • History or presence of any disease, surgical or medical condition of any major system organ class considered clinically significant by the investigator.
  • Laboratory parameter at screening and baseline outside of normal limits. For small deviations which could be attributed to the characteristics of the subjects (e.g. age) it will be to the discretion of the investigator to consider them as exclusive or not.
  • A positive Hepatitis B surface antigen or Hepatitis C test result.

Sites / Locations

  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Group 1 Treatment with serelaxin

Group 2 Treatment with serelaxin

Group 3 Treatment with serelaxin

Group 4 Treatment with serelaxin

Arm Description

Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin

Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment

Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval

Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment

Outcomes

Primary Outcome Measures

Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
The area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr)
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
The area under the serum concentration-time curve from time zero to infinity (AUCinf)
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
The observed maximum serum concentration following drug administration (Cmax)
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin

Secondary Outcome Measures

Percentage of patients with reported adverse events, serious adverse events and death.
Percentage of patients developing anti-RLX030 antibodies

Full Information

First Posted
June 7, 2013
Last Updated
December 17, 2020
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01875523
Brief Title
PK of Serelaxin in Severe Renal Impairment and ESRD
Acronym
CRLX030A2102
Official Title
A Single Dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Serelaxin in Patients With Severe Renal Impairment or End-Stage Renal Disease on Hemodialysis Compared to Matched Healthy Control Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Failure, Chronic, End-Stage Renal Disease
Keywords
Renal disease, renal impairment, End stage renal disease, Healthy volunteer, Pharmacokinetics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1 Treatment with serelaxin
Arm Type
Experimental
Arm Description
Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
Arm Title
Group 2 Treatment with serelaxin
Arm Type
Experimental
Arm Description
Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
Arm Title
Group 3 Treatment with serelaxin
Arm Type
Experimental
Arm Description
Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
Arm Title
Group 4 Treatment with serelaxin
Arm Type
Experimental
Arm Description
Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
Intervention Type
Drug
Intervention Name(s)
Serelaxin
Other Intervention Name(s)
RLX030
Primary Outcome Measure Information:
Title
Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Description
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
Time Frame
pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15
Title
The area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr)
Description
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
Time Frame
pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15
Title
The area under the serum concentration-time curve from time zero to infinity (AUCinf)
Description
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
Time Frame
pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15
Title
The observed maximum serum concentration following drug administration (Cmax)
Description
Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin
Time Frame
pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15
Secondary Outcome Measure Information:
Title
Percentage of patients with reported adverse events, serious adverse events and death.
Time Frame
From Day -21 to Day 15
Title
Percentage of patients developing anti-RLX030 antibodies
Time Frame
Day 1 (pre-treatment) and Day 15

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: All subjects - at least 50 years; body mass index (BMI) within the range of 18 - 35 kg/m2. Patients with severe renal impairment / ESRD Severe renal impairment (clinically significantly abnormal creatinine and creatinine clearance (15mL/min/1.73m2≤eGFR<30mL/min/1.73m2) or ESRD on hemodialysis. Sitting vital signs should be within the following ranges: oral body temperature between 35.0-37.5 °C systolic blood pressure, 110 to 170 mm Hg diastolic blood pressure, 60 to 105 mm Hg pulse rate, 45 - 100 bpm Healthy subjects eGFR > 90mL/min/1.73m2; matching in race, age (±10 years), gender, BMI (±15%) to a subject with renal impairment Subject must be in good health. Sitting vital signs should be within the following ranges: oral body temperature between 35.0-37.5 °C systolic blood pressure, 100 to 150 mm Hg diastolic blood pressure, 60 to 95 mm Hg pulse rate, 50 to 100 bpm Exclusion Criteria: All subjects History of clinically significant ECG abnormalities at Screening or Baseline. Pregnant or nursing (lactating) women Women of child-bearing potential unless they are using highly effective methods of contraception during dosing of study treatment. Sexually active males (incl. vasectomized men) must use a condom during intercourse while taking drug and for 2 weeks after stopping study medication. Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.). Patients with severe renal impairment / ESRD: Presence of any non-controlled and clinically significant disease, surgical or medical condition that could affect the study outcome or that would place the patient at undue risk as judged by the investigator. Hemoglobin levels below 9.0 g/dL at screening and baseline, other laboratory parameters at screening and baseline outside acceptable limits . Treatment with any cytostatic drug or autonomic alpha blocker. Healthy subjects: Use of any prescription drugs (other than hormonal contraception, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. History or presence of any disease, surgical or medical condition of any major system organ class considered clinically significant by the investigator. Laboratory parameter at screening and baseline outside of normal limits. For small deviations which could be attributed to the characteristics of the subjects (e.g. age) it will be to the discretion of the investigator to consider them as exclusive or not. A positive Hepatitis B surface antigen or Hepatitis C test result.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Grunstadt
ZIP/Postal Code
D-67269
Country
Germany

12. IPD Sharing Statement

Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13044
Description
Results for CRLX030A2102 can be found on the Novartis Clinical Trial Results Website

Learn more about this trial

PK of Serelaxin in Severe Renal Impairment and ESRD

We'll reach out to this number within 24 hrs